Valuation : Glenmark Pharmaceuticals Limited

Market Cap 688B 7.28B 6.27B 5.9B 5.39B 10.08B 10.11B 69.69B 27.04B 353B 27.35B 26.76B 1,137B P/E 2027 *
29.6x
P/E 2028 * 24.6x
Enterprise Value 651B 6.9B 5.94B 5.58B 5.1B 9.54B 9.57B 65.99B 25.61B 334B 25.9B 25.34B 1,076B EV / Sales 2027 *
3.88x
EV / Sales 2028 * 3.42x
Free-Float
51.04%
Yield 2027 *
0.16%
Yield 2028 * 0.16%
1 day-0.89%
1 week-3.09%
Current month-1.73%
1 month+7.89%
3 months+12.51%
6 months+15.57%
Current year+19.75%
1 week 2,420
Extreme 2420
2,532.4
1 month 2,222.5
Extreme 2222.5
2,537.6
Current year 1,842
Extreme 1842
2,537.6
1 year 1,792.6
Extreme 1792.6
2,537.6
3 years 722.1
Extreme 722.1
2,537.6
5 years 348.5
Extreme 348.5
2,537.6
10 years 161.65
Extreme 161.65
2,537.6
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2000
Director of Finance/CFO 54 27/05/2025
President - 15/09/2023
Director TitleAgeSince
Director/Board Member 58 -
Chairman 56 12/05/2011
Director/Board Member 86 14/08/2009
Change 5-day change 1-year change 3-year change Capi.($)
-0.89%-3.09%+18.78%+207.82% 7.28B
-0.89%-1.09%+19.16%+67.77% 48.26B
-1.72%-1.15%+45.80%+117.34% 40.5B
-0.70%-2.70%-10.84%+11.79% 11.85B
-2.01%-5.96%+10.47%+76.64% 11.83B
+2.31%0.00%+26.67%+153.33% 9.36B
+0.08%-4.11%+24.83%+43.80% 7.5B
-1.67%-0.35%+41.04%-11.59% 7.37B
-0.16%-2.36%-46.14%+16.28% 5.19B
-1.60%-2.59%+32.54%+102.62% 4.58B
Average -0.72%-2.14%+16.23%+78.58% 15.37B
Weighted average by Cap. -0.97%-1.74%+23.16%+83.37%

Financials

2027 *2028 *
Net sales 168B 1.78B 1.53B 1.44B 1.32B 2.46B 2.47B 17.02B 6.6B 86.16B 6.68B 6.53B 278B 187B 1.98B 1.71B 1.6B 1.47B 2.74B 2.75B 18.96B 7.36B 96.01B 7.44B 7.28B 309B
Net income 23.11B 245M 211M 198M 181M 339M 340M 2.34B 909M 11.86B 919M 899M 38.2B 27.71B 293M 253M 238M 217M 406M 407M 2.81B 1.09B 14.22B 1.1B 1.08B 45.8B
Net Debt -36.49B -386M -333M -313M -286M -535M -536M -3.7B -1.43B -18.72B -1.45B -1.42B -60.31B -48B -508M -437M -412M -376M -703M -705M -4.86B -1.89B -24.63B -1.91B -1.87B -79.34B
Logo Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Employees
16,946
Date Price Change Volume
04/09/26 ₹2,437.20 -0.89% 412,728
03/09/26 ₹2,459.00 -0.04% 481,343
02/09/26 ₹2,460.00 -0.42% 516,029
01/09/26 ₹2,470.40 -0.39% 679,565
31/08/26 ₹2,480.00 -1.39% 911,026
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2,437.20INR
Average target price
2,497.73INR
Spread / Average Target
+2.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLENMARK Stock